Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

Frigault MJ, Dhakal B, Jakubowiak AJ, Raje N, Banerjee K, Mu CJ, Hart KC, Shachar S, Andrews LP, Cheung LS, Griffin FM, Witter AR, Hyde M, Pham C, Gandra N, Shakya T, Rajan B, Cortesio C, Haile ST, Nowyhed H, Nair-Gupta P, Mitra P, Chan RJ, Kostic A, Heery CR, Rosenblatt J, Bishop MR

Open source

DOI: 10.1056/nejmoa2603527
Published: 2026 Sep 24
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2603527,
  title = {Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.},
  author = {Frigault MJ and Dhakal B and Jakubowiak AJ and Raje N and Banerjee K and Mu CJ and Hart KC and Shachar S and Andrews LP and Cheung LS and Griffin FM and Witter AR and Hyde M and Pham C and Gandra N and Shakya T and Rajan B and Cortesio C and Haile ST and Nowyhed H and Nair-Gupta P and Mitra P and Chan RJ and Kostic A and Heery CR and Rosenblatt J and Bishop MR},
  year = {2026},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2603527},
  url = {https://doi.org/10.1056/nejmoa2603527}
}

RIS

TY  - JOUR
TI  - Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
AU  - Frigault MJ
AU  - Dhakal B
AU  - Jakubowiak AJ
AU  - Raje N
AU  - Banerjee K
AU  - Mu CJ
AU  - Hart KC
AU  - Shachar S
AU  - Andrews LP
AU  - Cheung LS
AU  - Griffin FM
AU  - Witter AR
AU  - Hyde M
AU  - Pham C
AU  - Gandra N
AU  - Shakya T
AU  - Rajan B
AU  - Cortesio C
AU  - Haile ST
AU  - Nowyhed H
AU  - Nair-Gupta P
AU  - Mitra P
AU  - Chan RJ
AU  - Kostic A
AU  - Heery CR
AU  - Rosenblatt J
AU  - Bishop MR
PY  - 2026
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2603527
UR  - https://doi.org/10.1056/nejmoa2603527
ER  -

APA

MJ, F., B, D., AJ, J., N, R., K, B., CJ, M., KC, H., S, S., LP, A., LS, C., FM, G., AR, W., M, H., C, P., N, G., T, S., B, R., C, C., ST, H., H, N., P, N., P, M., RJ, C., A, K., CR, H., J, R., & MR, B. (2026). Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2603527

Source records

pubmed · retrieved 2026-09-25T13:20:44.119Z